Abstract
We analyzed trends in prescribing and overdose deaths related to propoxyphene (e.g., Darvon) before and after a 1978-80 informational campaign carried out by the US Food and Drug Administration and the drug's manufacturer through mailed warnings, face-to-face education of prescribers, press releases, and labeling changes. The goals included a reduction in propoxyphene use with alcohol or other CNS depressants, reduced prescribing of refills, and cessation of prescribing for patients at risk of abuse and misuse (suicide). We conducted time-series analyses of nationwide propoxyphene use data 1974-83 and analyzed data on drug overdose death rates covering a combined population of about 83 million. Segmented regression methods were used to determine if the informational program was associated with changes in trends of prescribing or overdose deaths. Comparison drug series were analyzed to control for other secular trends in prescribing. Nationwide propoxyphene use during the warnings continued a pre-existing decline of about 8 per cent per year, but this decline halted after the warnings. The no-refill recommendation had no impact on refill rates. The risk of overdose death per propoxyphene prescription filled has remained about constant since 1979. Sharper declines in misuse of such drugs will require stronger, more sustained regulatory or educational measures.
Full text
PDF![1518](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/538945a02cc4/amjph00263-0024.png)
![1519](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/54a68535bbff/amjph00263-0025.png)
![1520](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/4621f0e47596/amjph00263-0026.png)
![1521](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/97bf0870d4f9/amjph00263-0027.png)
![1522](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/c773cf9c5089/amjph00263-0028.png)
![1523](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce5a/1647178/b659ffea0d44/amjph00263-0029.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Avorn J., Chen M., Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982 Jul;73(1):4–8. doi: 10.1016/0002-9343(82)90911-1. [DOI] [PubMed] [Google Scholar]
- Avorn J., Soumerai S. B. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med. 1983 Jun 16;308(24):1457–1463. doi: 10.1056/NEJM198306163082406. [DOI] [PubMed] [Google Scholar]
- Baum C., Hsu J. P., Nelson R. C. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep. 1987 Jul-Aug;102(4):426–429. [PMC free article] [PubMed] [Google Scholar]
- Baum C., Kennedy D. L., Forbes M. B. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1985 Jun;28(6):686–692. doi: 10.1002/art.1780280613. [DOI] [PubMed] [Google Scholar]
- Böttiger L. E., Westerholm B. Drug-induced blood dyscrasias in Sweden. Br Med J. 1973 Aug 11;3(5875):339–343. doi: 10.1136/bmj.3.5875.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Evans C. E., Haynes R. B., Birkett N. J., Gilbert J. R., Taylor D. W., Sackett D. L., Johnston M. E., Hewson S. A. Does a mailed continuing education program improve physician performance? Results of a randomized trial in antihypertensive care. JAMA. 1986 Jan 24;255(4):501–504. [PubMed] [Google Scholar]
- Finkle B. S., McCloskey K. L., Kiplinger G. F., Bennett I. F. A national assessment of propoxyphene in postmortem medicolegal investigation, 1972-1975. J Forensic Sci. 1976 Oct;21(4):706–741. [PubMed] [Google Scholar]
- Finkle B. S. Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds: the USA experience. Hum Toxicol. 1984 Aug;3 (Suppl):115S–134S. doi: 10.1177/096032718400300113. [DOI] [PubMed] [Google Scholar]
- Gillings D., Makuc D., Siegel E. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Public Health. 1981 Jan;71(1):38–46. doi: 10.2105/ajph.71.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gruber C. M., Jr, Baptisti A., Jr, Bauer R. O., Jain A., Lash A. F., McMahon F. G. A multicenter analgesic study using single doses of placebo, propoxyphene and acetaminophen. J Med. 1977;8(1):35–51. [PubMed] [Google Scholar]
- Inman W. H., Adelstein A. M. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet. 1969 Aug 9;2(7615):279–285. doi: 10.1016/s0140-6736(69)90051-8. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Ahmann D. L., Taylor W. F., Schwartau N. A comparative evaluation of marketed analgesic drugs. N Engl J Med. 1972 Apr 13;286(15):813–815. doi: 10.1056/NEJM197204132861504. [DOI] [PubMed] [Google Scholar]
- Schaffner W., Ray W. A., Federspiel C. F., Miller W. O. Improving antibiotic prescribing in office practice. A controlled trial of three educational methods. JAMA. 1983 Oct 7;250(13):1728–1732. [PubMed] [Google Scholar]
- Soumerai S. B., Avorn J. Economic and policy analysis of university-based drug "detailing". Med Care. 1986 Apr;24(4):313–331. doi: 10.1097/00005650-198604000-00003. [DOI] [PubMed] [Google Scholar]
- Soumerai S. B., Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q Health Soc. 1984 Summer;62(3):447–474. [PubMed] [Google Scholar]
- Sunshine A., Slafta J., Gruber C., Jr A comparative analgesic study of propoxyphene, fenoprofen, the combination of propoxyphene and fenoprofen, aspirin, and placebo. J Clin Pharmacol. 1978 Nov-Dec;18(11-12):556–563. doi: 10.1002/j.1552-4604.1978.tb01585.x. [DOI] [PubMed] [Google Scholar]
- Tennant F. S., Jr Drug abuse in the US Army, Europe. JAMA. 1972 Sep 4;221(10):1146–1149. [PubMed] [Google Scholar]
- Wade O. L., Hood H. Prescribing of drugs reported to cause adverse reactions. Br J Prev Soc Med. 1972 Nov;26(4):205–211. doi: 10.1136/jech.26.4.205. [DOI] [PMC free article] [PubMed] [Google Scholar]